
|Podcasts|April 28, 2022
Diabetes Dialogue: April 2022 Edition
In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of the FDA's approval of semaglutide 2.0 mg, the use of novel glycemic control metrics, and a preview of ATTD 2022.
Advertisement
Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives is available in an audio-only format on
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial
2
10 Cardiology Headlines You Missed in May 2026
3
What Are the Lasting Consequences of Childhood-Onset Atopic Dermatitis?
4
Expert Consensus Offers Age-Specific Guidance for Genital Psoriasis Care
5

























































